Trial Profile
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Emiplacel (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Registrational; Therapeutic Use
- Acronyms PACE
- Sponsors Pluri
- 31 Jan 2024 Results evaluating whether PLX-PAD would increase amputation-free survival in people with CLTI who were not candidates for revascularization, published in the British Journal of Surgery
- 13 Mar 2023 ccording to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 27 May 2021 This trial has been discontinued in Czechia and Bulgaria according to European Clinical Trials Database record.